New weight management drugs are changing obesity care, and their impact hinges on how healthcare leaders respond. Discover how stakeholder actions could shape three potential futures for obesity care and the strategies leaders can implement to ensure optimal outcomes.

Use our resource to learn how to build a successful weight management program that effectively attracts new patients struggling with obesity, guides patients through their care journey, and keeps patients engaged in the long-term.

The weight management medication market is facing a crucial turning point. Learn about the five game-changing moments that will affect the use of GLP-1s for weight loss — from expanded indications to Medicare coverage — and find out what stakeholders should do now to prepare for the future.

Health plans and providers have historically hesitated to reimburse and prescribe weight loss drugs. Understand what has changed and which six questions you should ask when considering whether to prescribe weight management medications.

Weight-management drugs are big news for healthcare and mainstream media outlets alike, but the articles don’t always tell the whole story. Are these drugs an end to the obesity epidemic or a dangerous vanity fad? Are they here to stay? Who pays for them? Here are three headlines and Advisory Board’s take on what healthcare leaders really need to know.

Understand the major trends impacting diabetes and obesity care services and implications for cross-industry stakeholders.

The latest generation of weight management medications have sparked new questions about chronic obesity treatment. We answer five questions we’re hearing in conversations with healthcare leaders to help you understand how the medications differ from past iterations and their potential impacts.

Leaders have a lot of questions about protocol, supply, and coverage of weight loss drugs, and the consequences of patients using them for their unintended purpose. In this podcast episode, host Rachel (Rae) Woods walks through these questions with experts Kara Marlatt, Gaby Marmolejos, and Chloe Bakst and discuss the potential future of weight management in US healthcare.

Our primer includes key trends in bariatrics and telebariatrics, a discussion of investment considerations, and a sample case study from a leading health care organization with an established telebariatrics program.

While many health leaders are excited by the promise of new weight management drugs, including GLP-1s like Wegovy, others see new drugs with old problems. What can we learn from these perceptions? By looking at opinions about three existing medications, we explore the challenges and opportunities that lie ahead for weight management drugs.

As diabetes and obesity heightened individuals’ risk for severe COVID-19, the pandemic placed an outsized spotlight on these diseases over the last two years. We’ve identified four drivers that are reshaping the delivery of care for patients with diabetes and obesity.

Weight management services within health systems have traditionally focused on surgery. But as a new generation of weight management drugs sparks growing demand for comprehensive obesity care, some health systems are looking to reinvent their offerings. Learn how three early adopters are creating comprehensive, high-quality obesity services.

Recent breakthroughs in obesity management medications have put a spotlight on the weight management field. Here's how industry leaders can use this turning point to address three key missteps in our current approach and advance health outcomes for higher weight patients.

In this podcast episode, host Rachel Woods invites health equity expert Darby Sullivan and pharmacy expert Chloe Bakst to discuss how the healthcare industry thinks about weight management, why the current approaches may be doing more harm than good, and how healthcare leaders need to think differently about treating obesity and weight.

Hospital and health system leaders worry that Wegovy and similar weight management medications will erode their bariatric surgery volumes and revenue. However, when health systems and providers provide comprehensive obesity care, they can drive growth for surgical services by improving outcomes, increasing volume, and decreasing costs.